11th week of 2012 patent applcation highlights part 39 |
Patent application number | Title | Published |
20120064053 | Baby Lotion - The skin/body lotion composition of the present invention utilizes all natural plant derived components as a method for conditioning and moisturizing the skin. The invention provides good moisturizing and gives a smooth, soft touch feel upon conditioning of the skin, leaving no oily or greasy residue on the skin and is excellent in stability. | 2012-03-15 |
20120064054 | PHARMACEUTICAL COMPOSITIONS ACTIVE IN PREVENTING, STABILIZING AND TREATING ALZHEIMER'S DISEASE - The present invention relates to pharmaceutical compositions active in preventing, stabilizing and treating Alzheimer's disease and cognitive dysfunctions related thereto. | 2012-03-15 |
20120064055 | Methods for Treating Lysosomal Acid Lipase Deficiency in Patients - The present invention provides methods of treating LAL deficiency comprising administering to a mammal a therapeutically effective amount of lysosomal acid lipase with an effective dosage frequency. Methods of improving growth and liver function, increasing LAL tissue concentration, and increasing LAL activity in a human patient suffering from LAL deficiency are also provided. | 2012-03-15 |
20120064056 | DICHLORACETATE IN COMBINATION WITH CLINICALLY HIGH LEVELS OF CARDIOPROTECTIVE OR HEMODYNAMIC DRUGS - The present invention provides compositions and methods for using cardioprotective or hemodynamic drugs in combination with dichloroacetate enabling usage of cardioprotective or hemodynamic drugs at concentrations higher than used in normal clinical practice without increasing deleterious side effects normally associated with the cardioprotective or hemodynamic drug, thereby conferring added clinical benefit. The present invention teaches administration of DCA with cardioprotective or hemodynamic drugs as an adjunct therapy thereby conferring added clinical benefit to clinically recommended protocols. | 2012-03-15 |
20120064057 | NOVEL ADAMTS-13 MUTANT - The present invention provides a method of enhancing an enzymatic activity of ADAMTS-13 and/or a method of reducing reactivity to an anti-ADAMTS-13 neutralizing antibody as well as a mutant of ADAMTS-13 prepared by the methods. The method of the present invention is characterized by substituting at least one charged amino acid in a disintegrin-like domain, a cysteine-rich domain or a spacer domain of ADAMTS-13 other than the following amino acids with a different amino acid: arginine at position 326, aspartic acid at position 330, aspartic acid at position 343 and arginine at position 349 in the disintegrin-like domain, aspartic acid at position 480, arginine at position 488, arginine at position 498, arginine at position 507, aspartic acid at position 533 and aspartic acid at position 543 in the cysteine-rich domain, and glutamic acid at position 641 and arginine at position 660 in the spacer domain. The present invention also provides a therapeutic agent for thrombotic disease comprising as an active ingredient the mutant of ADAMTS-13 prepared by the method. | 2012-03-15 |
20120064058 | COMPOSITIONS FOR PROTEIN-BASED DIETARY PRODUCTS - A human use dietary product composition to reduce fat body mass without substantially reducing lean body mass, in obese or overweight patients includes a protein component and an amino acid additional component, the additional component containing a determined amount of lysine and/or tryptophan such that on the whole lysine and tryptophan in the composition have a weight ratio set between 2.5 and 4. To cope with typical protein-based diets drawbacks, the composition further includes an amino acid additional component with an amino acid selected from the group including lysine and/or tryptophan, in an amount such that on the whole the lysine and tryptophan in the composition have a weight ratio set between 2.5 and 4. The composition further contains a component that may be a polysaccharide or an enzyme, or a combination thereof. The enzyme may be α-Galactosidase, Lactase, an enzyme having a flatulence reducing action, or a combination thereof. | 2012-03-15 |
20120064059 | FUSION PROTEINS - A single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, or a fragment thereof, which protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of a nociceptive sensory afferent; a Targeting Moiety that is capable of binding to a Binding Site on the nociceptive sensory afferent, which Binding Site is capable of undergoing endocytosis to be incorporated into an endosome within the nociceptive sensory afferent; a protease cleavage site at which site the fusion protein is cleavable by a protease, wherein the protease cleavage site is located between the non-cytotoxic protease or fragment thereof and the Targeting Moiety; a translocation domain that is capable of translocating the protease or protease fragment from within an endosome, across the endosomal membrane and into the cytosol of the nociceptive sensory afferent. Nucleic acids encoding the fusion proteins, methods of preparing same and uses thereof are also described. | 2012-03-15 |
20120064060 | COMPOUND HAVING S1P RECEPTOR BINDING POTENCY AND USE THEREOF - Provided are: a compound represented by formula (I): | 2012-03-15 |
20120064061 | ADHESIVE COMPOSITION COMPRISING TANNIN, POLY(ETHYLENE GLYCOL), AND WATER, LOWER ALCOHOL OR MIXTURE THEREOF - Provided is an adhesive composition disclosed herein includes tannin, poly(ethylene glycol) and water. The adhesive composition has little toxicity, allows adhesion even in the absence of a thermosetting curing agent, and is hardly soluble in water to show moisture resistance, unlike known tannin adhesives. Therefore, the adhesive composition may be used as a medical adhesive, adhesive depot for sustained release of drug, anti-adhesion agent, cell/protein adsorption barrier and medical hemostatic applicable to various wet environments. | 2012-03-15 |
20120064062 | INHIBITORS OF BACTERIAL PLASMINOGEN ACTIVATORS - Organic compounds showing the ability to inhibit bacterial omptin proteases, specifically | 2012-03-15 |
20120064063 | Compositions of F(ab')2 Antibody Fragments - The present invention is directed to a pharmaceutical composition comprising F(ab′) | 2012-03-15 |
20120064064 | ANTIGEN-BINDING PROTEINS - The present invention relates to antigen binding proteins comprising an immunoglobulin heavy chain and an immunoglobulin light chain, wherein the heavy chain comprises an epitope binding domain linked to the n-terminus of CH1-CH2-CH3, and the light chain comprises an epitope binding domain linked to the n-terminus of CL, wherein one or more epitope-binding domains are linked to the C-terminus of the immunoglobulin heavy chain, and/or one or more epitope-binding domains are linked to the C-terminus of the immunoglobulin light chain, methods for making such proteins, and uses thereof. | 2012-03-15 |
20120064065 | Safe and functional humanized antibodies - The present invention is related to safe and functional antibodies for the therapeutic and diagnostic use in the treatment of an amyloidosis, a group of disorders and abnormalities associated with amyloid protein, such as Alzheimer's disease. | 2012-03-15 |
20120064066 | Monoclonal Antibodies to Hepatocyte Growth Factor - The present invention is directed toward a neutralizing monoclonal antibody to hepatocyte growth factor, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient. | 2012-03-15 |
20120064067 | THERAPEUTIC USE OF ANTI-CS1 ANTIBODIES - The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists. | 2012-03-15 |
20120064068 | THERAPEUTIC USE OF ANTI-CS1 ANTIBODIES - The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists. | 2012-03-15 |
20120064069 | THERAPEUTIC USE OF ANTI-CS1 ANTIBODIES - The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists. | 2012-03-15 |
20120064070 | MODULATION OF NKG2D - The present invention relates to methods and compositions for treating and/or preventing autoimmune and/or inflammatory disease. In particular, the present invention provides therapeutics for impairing the expansion and function of autoreactive T cells, NK cells and/or NKT cells, by modulating NKG2D. | 2012-03-15 |
20120064071 | TREATMENT OF CANCER - Provided are methods relating to compositions that include a CDP-topoisomerase inhibitor, e.g., a CDP-camptothecin or camptothecin derivative conjugate, e.g., CRLX101. | 2012-03-15 |
20120064072 | Combination Cancer Therapy Comprising Administration of an EGFR Inhibitor and an IGF-1R Inhibitor - A method of treating cancer comprising: (a) identifying a patient having cancer that initially responded to IRS1 agent therapy and that has resumed progression; (b) administering an effective regimen comprising the same or a different IRS1 agent and an IGF-1 R inhibitor administered together or sequentially. | 2012-03-15 |
20120064073 | IL-17 HOMOLOGOUS POLYPEPTIDES AND THERAPEUTIC USES THEREOF - The present invention is directed to novel polypeptides having sequence identity with IL-17, IL-17 receptors and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases. | 2012-03-15 |
20120064074 | ANTIGEN BINDING DOMAINS - A process for the production of an antigen specific antigen binding domain using a transformed host containing an expressible DNA sequence encoding the antigen specific antigen binding domain, wherein the antigen specific antigen binding domain is derived from a variable region of the immunoglobulin isotype NAR found in fish. | 2012-03-15 |
20120064075 | CHIMERIC FACTOR VII MOLECULES WITH ENHANCED HALF LIFE AND METHODS OF USE - The present invention relates to novel proteins and methods of using chimeric Factor VIIa polypeptides. | 2012-03-15 |
20120064076 | METHODS AND COMPOSITION TO REGULATE IRON METABOLISM - The present invention provides new systems and strategies for the regulation of iron metabolism in mammals. In particular methods of using agonists and antagonists of TGF-β superfamily members to modulate the expression or activity of hepcidin, a key regulator of iron metabolism, are described. The inventive methods find applications in the treatment of diseases associated with iron overload, such as juvenile hemochromatosis and adult hemochromatosis, and in the treatment of diseases associated with iron deficiency, such as anemia of chronic disease and EPO resistant anemia in end-stage of renal disease. The present invention also relates to screening tools and methods for the development of novel drugs and therapies for treating iron metabolism disorders. | 2012-03-15 |
20120064077 | STABLE AND SOLUBLE ANTIBODIES INHIBITING TNF ALPHA - The present invention relates to particularly stable and soluble scFv antibodies and Fab fragments specific for TNFα, which comprise specific light chain and heavy chain sequences that are optimized for stability, solubility, in vitro and in vivo binding of TNFα, and low immunogenicity. Said antibodies are designed for the diagnosis and/or treatment of TNFα-related disorders. The nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed. | 2012-03-15 |
20120064078 | Novel Tumor Biomarket - The present invention relates to the diagnosis and treatment of cancer, and specifically to a method of diagnosing the presence or metastasis of cancer by detecting plasma Hsp90α having the amino acid sequence of SEQ ID No.1 as a tumor marker. In addition, the present invention also relates to a method for the treatment of cancer and metastasis. | 2012-03-15 |
20120064079 | Compositions and Methods for Preventing Erythropoietin-Associated Hypertension - The inventors have discovered that both soluble erythropoietin-binding protein and antibodies against the erythropoietin-binding protein, when they are administered to a mammal along with erythropoietin (Epo), prevent or reduce the blood pressure increase normally caused by erythropoietin, while not affecting the hematocrit increase that is the purpose of Epo treatment. The invention provides a method of treating anemia in a mammal involving: administering erythropoietin (Epo) to the mammal; and administering to the mammal an agent selected from a soluble Epo-binding protein (Epo-bp), a recognition protein that binds Epo receptor on an extracellular soluble portion of the Epo receptor, and a combination thereof. The invention also provides a method of reducing hypertension in a mammal receiving Epo, and pharmaceutical compositions containing a soluble Epo-bp and/or a recognition protein that binds Epo receptor on an extracellular soluble portion of the Epo receptor. | 2012-03-15 |
20120064080 | Human LY6-Big Molecules and Methods of Use - The present invention is directed to human Ly6-BIG molecules and their use in diagnostic, prognostic, and treatment methods for colon, lung and other cancers, in preventing the reoccurrence of such cancers, and in diagnostic, prognostic, and treatment methods for autoimmune disorders and AIDS. | 2012-03-15 |
20120064081 | ANTI-KIR3D ANTIBODIES - The present invention provides antigen-binding proteins capable of binding to KIR3D polypeptides. The antibodies have increased activity in the treatment of disorders characterized by KIR3DL2-expressing cells, particularly CD4+ T cells, including malignancies such as Mycosis Fungoides and Sézary Syndrome. | 2012-03-15 |
20120064082 | AMINOACYL TRNA SYNTHETASES FOR MODULATING HEMATOPOIESIS - Hematopoietic-modulating compositions are provided comprising aminoacyl-tRNA synthetase polypeptides, including active fragments and/or variants thereof, as well as compositions comprising related agents such as antibodies and other binding agents. Also provided are methods of using such compositions in the treatment of conditions that benefit from the modulation of hematopoiesis. | 2012-03-15 |
20120064083 | THERAPEUTIC USE OF ANTI-CS1 ANTIBODIES - The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists. | 2012-03-15 |
20120064084 | SIGNAL TRANSDUCTION PROTEIN TAB2 - A novel signal transducer TAB2 which acts as an adapter molecule of TRAF6 and TAK1 and mediates the activation of TAK1 in the signal transduction of IL-1 was isolated. TAB2 induced the activation of NF-κB and JNK by IL-1. The signal transduction by IL-1 was inhibited by inhibiting the signal transduction of TAB2 with the use of a dominant negative mutant of TAB2. A compound inhibiting the signal transduction in TAB2 is useful as an anti-inflammatory drug. | 2012-03-15 |
20120064085 | ANTI-INFLUENZA M2e ANTIBODY - Humanized recombinant and monoclonal antibodies specific for the ectodomain of the influenza virus M2 ion channel protein are disclosed. The antibodies of the invention have anti-viral activity and may be useful as anti-viral therapeutics and/or prophylactic/vaccine agents for inhibiting influenza virus replication and for treating individuals infected with influenza. | 2012-03-15 |
20120064086 | HIGH CONCENTRATION ANTIBODY AND PROTEIN FORMULATIONS - The present application relates to highly concentrated antibody and protein formulations with reduced viscosity that are stable, relatively isotonic and are of low turbidity. The formulations are particularly suitable for subcutaneous administration. The application further describes articles of manufacture containing such formulations and method for using them to treat disorders treatable by the formulated antibody or protein. | 2012-03-15 |
20120064087 | METHODS TO DIAGNOSE A REQUIRED REGULATION OF TROPHOBLAST INVASION - Methods are provided for the diagnosis and treatment of patients with increased risk of preeclampsia. The methods involve measuring levels of TGF-β | 2012-03-15 |
20120064088 | METHODS OF TREATING ANEURYSM - The present invention is directed to a method for treating aneurysms in vascular tissue. The method includes administering a bisphosphonate compound to a subject in an amount which is effective against the formation or progression of aneurysm, or which is effective to induce regression of an established aneurysm. In alternative methods, an anti-RANKL neutralizing antibody is administered to the subject to achieve analogous anti-aneurysm effect. The methods of particular advantage in the treatment of subjects having an abdominal aortic aneurysm, a relatively common, and life-threatening, condition. | 2012-03-15 |
20120064089 | ANTI-CXCL16 AND ANTI-CXCR6 ANTIBODIES FOR THE PREVENTION AND TREATMENT OF CANCER AND CANCER CELL MIGRATION - Methods for prevention or inhibition of the growth or metastasis of cancer cells in a subject are disclosed. One method comprises the step of administering to the subject a therapeutically effective amount of an antibody to the chemokine CXCL16 and/or the chemokine receptor CXCR6. Another method comprises the step of administering to the subject a therapeutically effective amount of an expression vector that expresses an antibody to the chemokine CXCL16 and/or the chemokine receptor CXCR6. | 2012-03-15 |
20120064090 | THERAPEUTIC AGENT FOR CANCER HAVING REDUCED SENSITIVITY TO MOLECULAR TARGET DRUG AND PHARMACEUTICAL COMPOSITION FOR ENHANCING SENSITIVITY TO MOLECULAR TARGET DRUG - Provided are a pharmaceutical composition which enhances the sensitivity of a cancer to a molecular target drug, such as gefitinib and erlotinib, wherein the cancer has resistance to the molecular target drug, and a cancer therapeutic agent effective against a cancer having resistance to a molecular target drug, such as gefitinib and erlotinib. The pharmaceutical composition comprising an HGF-MET receptor pathway inhibitor enhances the sensitivity of a cancer to a molecular target drug, such as gefitinib and erlotinib, even though the cancer has resistance to the molecular target drug. The cancer therapeutic agent comprising a molecular target drug in combination with an HGF-MET receptor pathway inhibitor is effective against a cancer having resistance to the molecular target drug. | 2012-03-15 |
20120064091 | DYSFUNCTION OF THE MITOCHONDRIAL RESPIRATORY CHAIN, METHODS FOR DIAGNOSIS, TREATMENT AND FOLLOW-UP - The invention relates to a method, of assessing whether a subject is affected with or at risk for developing a dysfunction of the mitochondrial respiratory chain, the method comprising determining the concentration of fibroblast growth factor 21 (FGF21) in a biological sample from the subject, and comparing it to the concentration of FGF21 in a biological sample from at least one normal control, wherein an increase in the concentration of FGF21 in the biological sample from the subject when compared to the concentration of FGF21 in the biological sample from at least one normal control is indicative of occurrence of the dysfunction of the mitochondrial respiratory chain in said subject, or of risk for developing said dysfunction. The invention also relates to a method for follow-up of a dysfunction of the mitochondrial respiratory chain in a subject diagnosed with but not being treated for said dysfunction, to a method for treating a subject having a dysfunction of the mitochondrial respiratory chain, to a method for determining whether a dysfunction of the mitochondrial respiratory chain in a subject diagnosed with and being treated for said dysfunction is responding to the treatment, and for selecting patients for clinical trials. | 2012-03-15 |
20120064092 | Novel Target for Regulating Multiple Sclerosis - Methods are provided for decreasing demyelinating inflammatory disease in a subject by inhibiting the activity of chemokine-like receptor 1 (CMKLR1). Methods are also provided for screening for agents that find use in treating demyelinating inflammatory disease in a subject. | 2012-03-15 |
20120064093 | ANTIBODY - The invention relates to antibodies to | 2012-03-15 |
20120064094 | Serotonin 5-HT3 Receptor Antagonists for Use in the Treatment of Lesional Vestibular Disorders - The invention relates to serotonin 5-HT3 receptor antagonists or inhibitors of serotonin 5-HT3 receptor gene expression for use in the treatment of a lesional vestibular disorder. | 2012-03-15 |
20120064095 | TOLL-LIKE RECEPTOR 3 ANTAGONISTS FOR THE TREATMENT OF METABOLIC AND CARDIOVASCULAR DISEASES - Toll Like Receptor 3 (TLR3) antibody antagonists, polynucleotides encoding TLR3 antibody antagonists or fragments thereof, and methods of making and using the foregoing are disclosed. | 2012-03-15 |
20120064096 | BTLA Antibodies and Uses Thereof - The invention relates to BTLA antibodies that block BTLA-HVEM interaction and uses thereof. | 2012-03-15 |
20120064097 | Enhanced Binding of Pro-Inflammatory Cytokines by Polysaccharide-Antibody Conjugates - We provide monoclonal antibodies against interleukin-1β and tumor necrosis factor-α that remain biologically active in vitro when conjugated to high molecular weight polysaccharides. We report enhanced binding of these cytokines when their monoclonal antibodies are conjugated to alginate compared to non-conjugated monoclonal antibodies. In cell assays, polysaccharide-antibody constructs of the invention inhibited cytokine signaling to comparable levels as that of unmodified antibodies. Conjugation of cytokine-neutralizing antibodies to high molecular weight polymers enhances the affinities cytokine-binding moieties used as anti-inflammatory therapeutics. | 2012-03-15 |
20120064098 | Intracoronary Device And Method Of Use Thereof - Engraftment of therapeutic cells and agents to a target site in an organism is enhanced by mechanical, chemical and biological methods and systems. | 2012-03-15 |
20120064099 | COMPOUNDS THAT INHIBIT NFKB AND BACE1 ACTIVITY - The present invention relates to compounds with activity as BACE1 and NFκB modulators, and methods for treating, preventing, or ameliorating neurodegenerative diseases, such as Alzheimer's disease. The present invention is also directed to the treatment of diseases related to dysfunction of cell proliferation, the immune system and/or inflammation using such compounds or pharmaceutical compositions containing such candidate compounds. | 2012-03-15 |
20120064100 | BIOMARKERS AND USES THEREOF - The present invention provides markers of regulatory T (Treg) cells, preferably, cell surface markers of Treg cells and uses of those markers or compounds that bind thereto to identify or isolate Treg cells or to diagnose/prognose/treat/prevent Treg-mediated conditions. The present invention also provides methods for identification and/or isolation of Treg cell subpopulations and such isolated subpopulations of Treg cells. | 2012-03-15 |
20120064101 | Compounds and Methods Useful for Detection and Treatment of Cancer - The present invention relates to compounds and methods useful for the detection and treatment of disorders associated with frameshift mutations in coding microsatellite regions. The compounds and methods are applicable in cancers, especially of DNA mismatch repair deficient (MMR) sporadic tumours and HNPCC associated tumours. The compounds are useful for detection of disorders and in therapy such as immuno-therapy. The diagnostic methods relate to diagnosis and prognostic assessment of disorders associated with frameshift polypeptides originating from frameshift mutations in coding microsatellite regions of genes based on the detection of immunological entities directed against said frameshift polypeptides in body fluids. With respect to the treatment of cancer, the invention pertains to methods which use immuno therapy with combinatorial mixtures of tumour specific frameshift peptides to elicit a cytotoxic T-cell response specifically directed against tumour cells for prevention and curative treatment of cancers and precancers. | 2012-03-15 |
20120064102 | PEPTIDE INDUCING XAGE-1B-SPECIFIC IMMUNE REACTION AND UTILIZATION OF SAME - The object of the present invention is to clarify functions of XAGE-1b and to develop a vaccine therapy for cancer based on XAGE-1b. Humoral immunity or cellular immunity is induced against XAGE-1b in lung cancer, by use of a peptide comprising an amino acid sequence of any one of (a) through (e) or by use of a peptide comprising an amino acid sequence of any one of (f) through (k). | 2012-03-15 |
20120064103 | COMBINATIONS OF MENINGOCOCCAL FACTOR H BINDING PROTEIN AND PNEUMOCOCCAL SACCHARIDE CONJUGATES - An immunogenic composition comprising: (i) a conjugated pneumococcal capsular saccharide; and (ii) a meningococcal factor H binding protein (fHBP) antigen, and not including meningococcal outer membrane vesicles, is useful for immunising a subject against bacterial meningitis. | 2012-03-15 |
20120064104 | COMBINATIONS INCLUDING PNEUMOCOCCAL SEROTYPE 14 SACCHARIDE - Meningococcal lipooligosaccharide and pneumococcal serotype 14 capsular saccharide share an antigen that can cross-react with human tissue. The invention provides various ways of minimising the production of autoreactive antibodies when these two antigens are co-administered. | 2012-03-15 |
20120064105 | Engineered Type IV Pilin of Clostridium difficile - The present invention relates to engineered | 2012-03-15 |
20120064106 | FLAGELLIN FUSION PROTEINS AND USE THEREOF TO INDUCE IMMUNE RESPONSES AGAINST PSEUDOMONAS AERUGINOSA - The invention provides compositions and fusion proteins comprising a flagellin adjuvant and a | 2012-03-15 |
20120064107 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE - Provided are methods relating to the use of CDP-therapeutic agent conjugates for the treatment of autoimmune disease, inflammatory disease, or cancer. Also provided are CDP-therapeutic agent conjugates, particles comprising CDP-therapeutic agent conjugates, and compositions comprising CDP-therapeutic agent conjugates. | 2012-03-15 |
20120064108 | GLYCOCONJUGATE VACCINES - Glycoconjugate vaccines and methods of preparing and using the same are described. | 2012-03-15 |
20120064109 | IMMUNOGENIC COMPOSITION AND USES THEREOF - The present invention provides an immunogenic composition comprising an antigen and a dendritic cell targeting component. A charged group is covalently attached to a dendritic cell ligand and is electrostatically associated with the dendritic cell targeting component. | 2012-03-15 |
20120064110 | SYNTHETIC NANOCARRIER VACCINES COMPRISING PEPTIDES OBTAINED OR DERIVED FROM HUMAN INFLUENZA A VIRUS HEMAGGLUTININ - This invention relates to compositions and methods that can be used immunize a subject against influenza. Generally, the compositions and methods include peptides obtained or derived from human influenza A virus hemagglutinin. | 2012-03-15 |
20120064111 | ATTENUATED VACCINES FOR NON-SEGMENTED NEGATIVE SENSE RNA VIRUSES - The invention relates to an attenuated non-segmented negative-sense RNA virus characterized by at least one mutation in the L gene wherein the mutation reduces viral replication, the methods of manufacturing and methods of use. | 2012-03-15 |
20120064112 | RECOMBINANT NEWCASTLE DISEASE VIRUSES USEFUL AS VACCINES OR VACCINE VECTORS - The present invention concerns an antigenomic RNA of Newcastle Disease virus (NDV) carrying one or more foreign genes inserted before NP gene, between P and M genes, and/or between HN and L genes. The invention is also directed toward a cDNA encoding a recombinant antigenomic RNA having one or more foreign genes inserted according to the invention, a cell containing the cDNA, a plasmid comprising the cDNA, a cell containing the plasmid, a cell containing the recombinant antigenomic RNA, and a recombinant NDV containing the recombinant antigenomic RNA of the invention, such as a recombinant NDV carrying one or more foreign genes recovered from transcription of the cDNA or the plasmid in a competent cell. The recombinant NDV carrying the one or more foreign genes can be used as a vaccine or vaccine vector. | 2012-03-15 |
20120064113 | Novel Attenuated Poliovirus - A novel and stable attenuated poliovirus, which replicates in neuroblastoma cells, is produced by engineering an indigenous replication element (cre), into the 5′ non-translated genomic region and inactivating the native cre element located in the coding region of 2C (mono-crePV). The stably attenuated poliovirus replicates in a neuroblastoma model (Neuro-2a | 2012-03-15 |
20120064114 | USE OF E. COLI SURFACE ANTIGEN 3 SEQUENCES FOR THE EXPORT OF HETEROLOGOUS ANTIGENS - The present invention provides an export signal system based on | 2012-03-15 |
20120064115 | RECOMBINANT VIRUS-LIKE PARTICLES ENCODED BY MULTI-GENE VECTOR - The invention describes novel virus-like particles for use as vaccines, diagnostic tools and R&D tools based on recombinant DNA and cell cultivation techniques for production. The recombinant virus-like particles of the invention are assembled by polypeptide chains that incorporate several, in particular two or more, different epitopes which are selected either (a) from different viral strains of the same virus and/or (b) from different serotypes of the same virus and/or (c) from different viral strains specific for different hosts. These epitopes are then displayed on the particle surface. | 2012-03-15 |
20120064116 | INFLUENZA NUCLEIC ACID MOLECULES AND VACCINES MADE THEREFROM - Provided herein are nucleic acid sequences that encode novel consensus amino acid sequences of HA hemagglutinin, as well as genetic constructs/vectors and vaccines expressing the sequences. Also provided herein are methods for generating an immune response against one or more Influenza A serotypes using the vaccines that are provided. | 2012-03-15 |
20120064117 | TETRAVALENT INFLUENZA VACCINE AND USE THEREOF - Disclosed herein is the finding that baculovirus display of multiple influenza virus hemagglutinin (HA) proteins elicits broadly reactive immune responses against influenza. Thus provided herein are recombinant baculovirus vectors having a first, second, third and fourth nucleic acid sequence, each encoding an influenza hemagglutinin (HA) fusion protein. The first, second, third and fourth nucleic acid sequences each encode an influenza HA with a different amino acid sequence. Also provided are recombinant baculoviruses displaying a first, second, third and fourth influenza virus HA fusion protein in the baculovirus envelope, wherein each HA fusion protein comprises a different HA amino acid sequence. Tetravalent influenza virus vaccines comprising the recombinant baculoviruses disclosed herein are further provided. In addition, methods of immunizing a subject against influenza virus using the tetravalent influenza virus vaccines are provided. In particular examples of the compositions and methods disclosed herein, the HA polypeptides are from H5N1 influenza virus. | 2012-03-15 |
20120064118 | BACTERIA STRAINS HAVING A HIGH ANTI-INFLAMMATORY ACTIVITY - The present invention relates to probiotic bacteria strains having a high anti-inflammatory activity. The present invention relates to bacteria strains as strongly inducers of Interleukin-10 (IL-10) production. In particular, the present invention relates to the anti-inflammatory activity shown by said bacteria strains due to its enhancement of IL-10 production in peripheral blood mononuclear cells, with on the other hand a low capability to stimulate the production of the pro-inflammatory 11-12, thus leading to a high IL-10/IL-12 ratio. Further, the present invention relates to the use of at least one bacterium strain for the preparation of a composition for the prevention or treatment of the inflammatory bowel diseases (IBD) and irritable bowel syndrome (IBS). Finally, the present invention relates to food products, such as probiotic dietary supplements containing at least one probiotic bacterium strain, as an active ingredient. | 2012-03-15 |
20120064119 | NEISSERIAL VACCINE COMPOSITIONS COMPRISING A COMBINATION OF ANTIGENS - The present invention relates to immunogenic compositions and vaccines for the treatment and prevention of Neisserial disease. Immunogenic compositions of the invention contain combinations of antigens selected from at least two different classes of antigens including adhesins, autotransporter proteins, toxins, iron acquisitions proteins and membrane-associated protein (preferably integral outer membrane protein)s. Such combinations of antigens are able to target the immune response against different aspects of the neisserial life cycle, resulting in a more effective immune response. | 2012-03-15 |
20120064120 | NEISSERIAL VACCINE COMPOSITIONS COMPRISING A COMBINATION OF ANTIGENS - The present invention relates to immunogenic compositions and vaccines for the treatment and prevention of Neisserial disease. Immunogenic compositions of the invention contain combinations of antigens selected from at least two different classes of antigens including adhesins, autotransporter proteins, toxins, iron acquisitions proteins and membrane-associated protein (preferably integral outer membrane protein)s. Such combinations of antigens are able to target the immune response against different aspects of the neisserial life cycle, resulting in a more effective immune response. | 2012-03-15 |
20120064121 | PYRIDINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES - The invention relates to compounds that are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders. | 2012-03-15 |
20120064122 | TREATMENT OF AUTOIMMUNE INFLAMMATION USING MIR-155 - The present disclosure relates to the finding that microRNA-155 plays a role in the development and activity of CD4+ T cells. CD4+ T cell development and function, particularly T | 2012-03-15 |
20120064123 | Composition for a topical ophthalmic clear colloidal liquid which undergoes a liquid-gel phase transition in the eye - The present invention is directed to a topical ophthalmic composition for a liquid comprised of clear colloidal polar nanolipids delivered in submicron sized particles (Nanopids™), aqueous colloidal lubricants, aqueous polymers, emulsifies, and a unique stabilizing buffer system, which undergoes a liquid-gel phase transition in the eye. Said composition is designed to deliver advanced eye lubricants, protect the three (3) layers of corneal film from dryness, and provide a unique system of Dry Eye treatment that addresses and treats all three layers of corneal tear film. Said composition is further designed to provide a superior delivery system of various Active Pharmaceutical Ingredients (APIs), and/or anti-infective/antibiotic/anti-fungal agents, accepted as safe and efficacious for ophthalmic use. | 2012-03-15 |
20120064124 | MACROLIDE DOSAGE FORMS - Provided is a drug delivery composition comprising at least one polymer and at least one active agent; wherein the active agent is present in crystalline form on at least one region of an outer surface of the composition and wherein active agent surface content is adjusted to provide a selected active agent release profile. | 2012-03-15 |
20120064125 | AGR-MEDIATED INHIBITION OF METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS - The present invention involves the use of activators of bacterial Agrquoroum-sensing systems to prevent or reverse biofilm formation in methicillin resistant | 2012-03-15 |
20120064126 | DRY POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES - The present invention is directed toward respirable dry particles for delivery of divalent metal cation salts and/or monovalent cation salts to the respiratory tract and methods for treating a subject having a respiratory disease and/or infection. | 2012-03-15 |
20120064127 | COMPOSITION FOR IMPROVING MEMBRANE COMPOSITION AND FUNCTIONING OF CELLS - It has now been found that after administration to a diseased person or person that is at risk for developing such disease of a neutraceutical or pharmaceutical composition that comprises
| 2012-03-15 |
20120064128 | NANO-METALLIC ALLOY DELIVERY SYSTEM FOR TREATMENT OF INFECTED CELLS AND LEGIONS - A system for delivering nano-metallic alloys to infected cells in a patient is disclosed. The nano-metallic alloy may be formed from binary, triple, or quadruple elemental compositions complexed in predetermined percentages of monosodium phosphate monohydrate and disodium phosphate heptahydrate. The nano-metallic alloy may be capable of eliminating infectious microorganisms within infect cells or legions without harming the cells or tissues. The system may also include a method of administering a predetermined concentration of the nano-metallic alloy in the complexing solution in the vicinity of the infected cells of legions to kill the foreign matter. | 2012-03-15 |
20120064129 | GASTRIC RETAINED GABAPENTIN DOSAGE FORM - A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form. | 2012-03-15 |
20120064130 | METHOD FOR IMPREGNATION WITH SUPERCRITICAL CO2 - The present invention relates to a batch method for impregnating a nonporous polymer pharmaceutical carrier with an active substance, characterised in that said method includes the following consecutive steps: a) mixing the active substance and the nonporous polymer pharmaceutical carrier, the pharmaceutical carrier being in a solid form and insoluble in supercritical CO | 2012-03-15 |
20120064131 | SILVER-BASED INORGANIC ANTIMICROBIAL AGENT AND METHOD FOR PREPARING THE SAME - Disclosed are a powder of a silver-based inorganic antimicrobial agent with superior dispersability or water permeability, composed of silver-supporting hexagonal zirconium phosphate, and an antimicrobial product and a water processing material using the silver-based inorganic antimicrobial agent powder. The silver-based inorganic antimicrobial agent containing hexagonal zirconium phosphate crystals, which has a particle size distribution to enable easy handling as a powder and contribute to exhibition of antimicrobial properties, can be prepared by a preparation method including wet-heating zirconium carbonate. When the silver-based inorganic antimicrobial agent wherein particles with a size of 10 μm to 100 μm are 90% or more on a volume basis is kneaded into resin products, since aggregation or the like may not occur and the silver-based inorganic antimicrobial agent can be easily exposed on the surface of molded articles, antimicrobial effects are thus readily exhibited on the surface. | 2012-03-15 |
20120064132 | ANTIBACTERIAL MEDICAL EQUIPMENT AND METHOD FOR PRODUCING THE SAME - An object of the present invention is to provide an antibacterial medical equipment which has sufficient antibacterial activity in vivo and is excellent in compatibility with living tissues, and also can maintain antibacterial activity over a long period and has high safety. | 2012-03-15 |
20120064133 | Multiparticulate Controlled-Release Selective Serotonin Reuptake Inhibitor Formulations - Multiparticulate controlled-release selective serotonin reuptake inhibitor (SSRI) formulations for oral administration, which comprise subunits of a SSRI or a pharmaceutically acceptable salt thereof which are not coated with a rate-controlling polymer, are provided. Methods for preparation and use of these formulations are also provided. | 2012-03-15 |
20120064134 | COLOR ENHANCEMENT UTILIZING UP CONVERTERS AND DOWN CONVERTERS - A light emitting composition including first color emitters and second color emitters. The first color emitters are configured to emit, upon exposure to an energy source, visible light at a target color in response to absorption of energy across a first band of wavelengths. The second color emitters are configured to emit, upon exposure to the energy source, visible light at the target color in response to absorption of energy across a second band of wavelengths. The light intensity observable at the target color is enhanced relative to reflected white light without emission from the first and second color emitters. The light emitting composition can be a part of a paint, an ink, a fabric, a thread, a road sign, a highway marking, an automobile, a boat, a plane, a reflector, a building product, a concrete product, an epoxy product, a jewelry product, colored contact lens, a candle product, a rubber product, a plastic product, or other colored surface. | 2012-03-15 |
20120064135 | Benzoyl Peroxide Composition, Methods for Making Same, and Pharmaceutical or Cosmetic Formulations Comprising Same, and Uses Thereof - The present invention relates to the preparation of compositions comprising benzoyl peroxide, with or without other additional active ingredients. The process involves introducing benzoyl peroxide, along with any other active ingredients present, into a fatty substance that contains and protects the ingredients that would otherwise be unstable when in contact with one another. The composition is designed to allow all ingredients to become available for skin contact or skin absorption when the fatty substance softens and/or melts as the composition is applied to the skin. The benzoyl peroxide may be pre-micronized to a particle distribution size of about d | 2012-03-15 |
20120064136 | ANTI-AGING AND WRINKLE TREATMENT METHODS USING NANOEMULSION COMPOSITIONS - The present invention relates to methods for treating, preventing, minimizing, and/or diminishing signs of aging in the skin comprising administering to the subject in need thereof a nanoemulsion composition. | 2012-03-15 |
20120064137 | TWO-LAYER SEPARATE TYPE HAIR COSMETIC COMPOSITION - A non-aerosol two-layer separate type hair cosmetic composition containing components (A) and (B) at a mass ratio (A)/(B) of from 0.2 to 10:
| 2012-03-15 |
20120064138 | BIOCIDAL COMPOSITION - The present invention relates to a biocidal composition comprising an inorganic compound and a polymer where the inorganic compound has been prepared using a controlled precipitation technique. The biocidal compositions overcome the settling and agglomeration problems of conventional inorganic biocidal compositions and offer enhanced activity, consistency, and stable long term release of the active species. The invention also relates to a method of preparation of the compositions and to their use as a biocidal composition and in making or coating articles comprising it. | 2012-03-15 |
20120064139 | ANTIMICROBIAL SUCRALFATE PASTE METHODS AND COMPOSITIONS - Methods for the prevention and treatment of infection, preferably antibiotic resistant wound infection, using a paste formed by the reaction of sucralfate with an acid component are provided. Methods of preparing stable sucralfate compositions are disclosed. Compositions of and products containing the sucralfate paste are also described. | 2012-03-15 |
20120064140 | COMPOSITE NANOGRANULES FROM POLYMER/INORGANIC NANOPARTICLES, PREPARATION METHOD THEREOF AND USE OF THE SAME - Composite nanogranules from polymer/inorganic nanoparticle, especially first composite nanogranules which are formed from first polymer and inorganic nanoparticles, second composite nanogranules which are obtained by forming second polymer on the first composite nanogranules, third composite nanogranules which is obtained by forming third polymer on the second composite nanogranules, and N | 2012-03-15 |
20120064141 | Drug-Coated Balloon With Location-Specific Plasma Treatment - Method of coating an expandable member, e.g. balloon, is provided, the method comprising providing an expandable member having an outer surface. The method includes a plasma treatment with a supply of gas performed on at least a portion of the outer surface of the expandable member. A therapeutic agent is applied on at least the plasma treated portion of the outer surface of the expandable member after the plasma treatment is performed. The plasma treatment can reduce the adhesion of therapeutic agent to the surface of the expandable member. A medical device made by the disclosed method is also provided. | 2012-03-15 |
20120064142 | POLYMERIC PHARMACEUTICAL DOSAGE FORM IN SUSTAINED RELEASE - This invention relates to a polymeric pharmaceutical dosage form for the delivery, in use, of at least one pharmaceutical composition in a rate-modulated and site-specific manner. The dosage form comprises a biodegradable, polymeric, scaffold incorporating loaded with at least one active pharmaceutical ingredient (API). The polymer or polymers making up the scaffold degrade in a human or animal body in response to or in the absence of specific biological stimuli and, on degradation, release the API or APIs in an area where said stimuli are encountered. Preferably the polymeric scaffold is formed from poly (D1L-lactide) (PLA) and polymethacrylate (Eudragit S100/ES100) polymers. | 2012-03-15 |
20120064143 | INHIBITION OF MAMMALIAN TARGET OF RAPAMYCIN - Disclosed are microcapsules that include an inhibitor of the mammalian target of rapamycin (mTOR) within the microcapsules, and pharmaceutical compositions and kits that include the microcapsules. Also disclosed are methods for treating or preventing an age-related disease, condition, or disorder in a subject that involve administering to a subject a pharmaceutically effective amount of microcapsules that includes an inhibitor of mTOR within the microcapsules. | 2012-03-15 |
20120064144 | METHOD OF TREATING ECZEMA - The present invention relates to the treatment of eczema. More specifically, the invention relates to a new method of treating eczema through the epicutaneous route. In particular, the method of the invention comprises applying to a non eczematous area of the skin of the subject a skin patch device, comprising a composition, under conditions allowing a contact between said composition and the skin. The present invention also relates to the skin patch device. | 2012-03-15 |
20120064145 | WOUND DRESSING - The present invention discloses a wound dressing which may be a double-layer wound dressing, comprising a polymer material layer in combination with anti-infective antibiotics or anti-infective Chinese herb medicine at the upper layer of the wound dressing, and a porous carbon material layer capable of loading with skin-associated epithelial cells at the lower layer of the wound dressing. The wound dressing with the antibiotics can block effectively the invasion of bacteria in the external environment, thereby preventing the wound from secondary infection. While covering the wound site, the porous carbon material layer with the epithelial cells can thus provide the healthy epithelial cells and attract the surrounding healthy cells to aggregate for secreting collagen so as to promote the wound healing process. According to the present invention, there is an obviously enhancing effect on wound tissue regeneration, restoration and healing, and there is a grant development potential in clinical applications. | 2012-03-15 |
20120064146 | Wound care device - A wound care device for local treatment of pain in a wound, said device comprising an active pain relieving composition, the device being constructed in such a manner that the pain killing agent is released to the wound in such a way that substantially no effective systemic plasma concentration of the pain killing agent can be found and wherein a majority of said pain killing agent is in direct contact with the wound. | 2012-03-15 |
20120064147 | AGENT FOR IMPROVING TISSUE PENETRATION - The invention concerns a pharmaceutical preparation which improves penetration of active substances through the tissue membrane or barrier of the target organ. | 2012-03-15 |
20120064148 | PH-RESPONSIVE LIPOSOME - The present invention provides pH-responsive liposomes which are capable of holding a desired substance in an acidic pH environment and releasing the desired substance in a basic pH environment. | 2012-03-15 |
20120064149 | HIGH-CLARITY AQUEOUS CONCENTRATES OF 4-HEXYLRESORCINOL - The present invention relates to hexylresorcinol/water concentrates that are high in clarity, easily handled, and readily blended with other ingredients to form skin care compositions. | 2012-03-15 |
20120064150 | BIOCOMPATIBLE MATERIALS CONTAINING STABLE COMPLEXES OF TSG-6 AND HYALURONAN AND METHOD OF USING SAME - The present invention provides a biocompatible material in the form of a solid, a water insoluble cross-linked gel or a liposome, which contains a stable comples of TNF-stimulated gene 6 protein (TSG-6) and hyaluronan. | 2012-03-15 |
20120064151 | ENHANCED IMMUNE RESPONSE IN AVIAN SPECIES - The present invention relates to a method of immune activation which is effective for eliciting a non-antigen-specific immune response in a member of the avian species. The method is particularly effective for protecting a member of the avian species from infectious disease and treating animals inflicted with infectious disease. | 2012-03-15 |
20120064152 | Analgesic and Anti-Inflammatory Compositions Comprising Domperidone and Methods of Using Same - The present invention provides a method for eliciting an onset hastened analgesic and anti-inflammatory response and combating nausea in acute migraine attacks. This method comprises administering a pharmaceutical composition comprising more than one active ingredient, wherein said more than one active ingredient consist essentially of: | 2012-03-15 |